Dr. Michael O. Ojelabi, MD

Dr. Ojelabi practices at Gundersen Lutheran Medical Center - Dialysis in La Crosse, Wisconsin.

Dr. Ojelabi's NPI, 1760699003, was assigned on May 17, 2007. Dr. Ojelabi holds Wisconsin license 55788.

Dr. Ojelabi's primary practice is Gundersen Lutheran Medical Center - Dialysis, at 1910 South Ave, Heritage Building 2 West, La Crosse, WI 54601 in La Crosse County. The practice phone is (608) 775-3176.

Dr. Ojelabi's primary practice is Gundersen Lutheran Medical Center - Dialysis in La Crosse, Wisconsin. Dr. Ojelabi is also affiliated with Gundersen Lutheran Medical Center. The medical group on file is Gundersen Lutheran Medical Center. Dmand AI also links Dr. Ojelabi to 4 more hospitals, 2 medical groups and 1 group practice or clinic, each named with a free account. Dr. Ojelabi's employer is on file too: a dialysis center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ojelabi practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Ojelabi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Ojelabi's licenses on file in 3 states: Wisconsin, Iowa and Illinois.

CMS data shows 723 Medicare services from Dr. Ojelabi across 5 procedure codes in 2024, for 186 Medicare patients. Medicare paid $35,121 for them.

CMS counts 186 Medicare patients who saw Dr. Ojelabi in 2024. The largest group is 65 to 74, with 89 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 15% are also on Medicaid. Their average risk score is 2.09, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ojelabi's median patient age at 71, with 57% women.

In 2024, Dr. Ojelabi wrote 975 Medicare Part D claims for 181 patients. 92% of them were for generic drugs. CMS names the drug for 766 of them, across 19 drugs with 11 or more claims each, at $95,405 in total drug cost. In 2023, CMS named 401 claims across 11 drugs.

Dr. Ojelabi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ojelabi as offering telehealth.

Dmand AI links 3 papers to Dr. Ojelabi, published from 2019 to 2023. Dr. Ojelabi's most frequent co-authors are Aminah Jatoi, MD, Heidi D. Klepin, MD and Maria R. Baer, MD.

Dmand AI links Dr. Ojelabi to 10 clinical trials, 4 of them phase 3 studies. 10 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Adenocarcinoma of Lung and Glioblastoma. National Cancer Institute (NCI) sponsors the most, 9.

CMS Open Payments shows 1 general payment to Dr. Ojelabi from 1 drug or device company in 2021. Education make up the largest share, 100% of the total. Pfizer Inc. paid the most, $31.